Editorial: Type 2 diabetes, thiazolidinediones: Bad to the bone?

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 9, 2006, Pages 3276-3278

  Watts, Nelson B ^a,b   D'Alessio, David A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 25 HYDROXYVITAMIN D; PARATHYROID HORMONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; SOMATOMEDIN C; TROGLITAZONE; ANTIDIABETIC AGENT;

BONE DENSITY; CLINICAL TRIAL; EDITORIAL; EXPERIMENTAL MODEL; FRACTURE; GLUCOSE TOLERANCE TEST; HUMAN; HYPERCALCIURIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOMAGNESEMIA; INSULIN RESISTANCE; LIVER TOXICITY; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSTEOLYSIS; PRIORITY JOURNAL; RENAL DIABETES; RISK ASSESSMENT; SEX DIFFERENCE; SIDE EFFECT; AGED; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; MALE; NOTE; OSTEOPOROSIS;

AGED; AGED, 80 AND OVER; ANIMALS; BONE DENSITY; DIABETES MELLITUS, TYPE 2; FEMALE; FRACTURES, BONE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; OSTEOPOROSIS; THIAZOLIDINEDIONES;

EID: 33748748644     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-1235     Document Type: Editorial

References (25)

1. Heath III H, Melton III LJ, Chu C-P 1980 Diabetes mellitus and risk of skeletal fracture. N Engl J Med 303:567-570
2. Schwartz AV, Sellmeyer DE, Strotmeyer ES, Tylavsky FA, Feingold KR, Resnick HE, Shorr RI, Nevitt MC, Black DM, Cauley JA, Cummings SR, Harris TB; Health ABC Study 2005 Diabetes and bone loss at the hip in older black and white adults. J Bone Miner Res 20:596-603
3. Dobnig H, Piswanger-Sölkner JC, Roth M, Obermayer-Pietsch B, Tiran A, Strele A, Maier E, Maritschnegg P, Sieberer C, Fahrleitner-Pamme A 2006 Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab 91:3355-3363
4. Meyer HE, Tverdal A, Falch JA 1993 Risk factors for hip fracture in middle-aged Norwegian women and men. Am J Epidemiol 137:1203-1211
5. Forsen L, Meyer HE, Midthjell K, Edna T-H 1999 Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia 42:920-925
6. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR; Study of Osteoporotic Features Research Group 2001 Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 86:32-38
7. Nicodemus KK, Folsom AR 2001 Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 24:1192-1197
8. Ottenbacher KJ, Ostir GV, Peek MK, Goodwin JS, Markides KS 2002 Diabetes mellitus as a risk factor for hip fracture in Mexican American older adults. J Gerontol A Biol Sci Med Sci 57:M468-M653
9. Vestergaard P, Rejnmark L, Mosekilde L 2005 Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48:1292-1299
10. Taylor BC, Schreiner PJ, Stone KL, Fink HA, Cummings SR, Nevitt MC, Bowman PJ, Ensrud KE 2004 Long-term prediction of incident hip fracture risk in elderly white women: Study of Osteoporotic Fractures. J Am Geriatr Soc 52:1479-1486
11. Ivers RQ, Cumming RG, Mitchell P, Peduto AJ 2001 Diabetes and risk of fracture: the Blue Mountains Eye Study. Diabetes Care 25:1198-1203
12. Keegan TH, Kelsey JL, Sidney S, Quesenberry Jr CP 2002 Foot problems as risk factors for fractures. Am J Epidemiol 155:926-931
13. de Liefde II, Van der Klift M, De Laet CE, Van Daele PL, Hofman A, Pols HA 2005 Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 16:1713-1720
14. Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Bauer DC, Tylavsky FA, de Rekeneire N, Harris TB, Newman AB 2005 Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the Health, Aging and Body Composition Study. Arch Intern Med 165:1612-1617
15. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM 1995 Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332:767-773
16. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB, Cummings SR, for the Health, Aging and Body Composition (Health ABC) Study 2006 Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349-3354
17. Yki-Järvinen H. 2004 Thiazolidinediones. N Engl J Med 351:1106-1118
18. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA 2004 Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 89:4312-4319
19. Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, Syversen U, Reseland JE 2004 Adiponectin and its receptors are expressed in bone-forming cells. Bone 35:842-849
20. Luo XH, Guo L-J, Yuan L-Q, Xie H, Zhou HD, Wu XP, Liao EY 2005 Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 309:99-109
21. Watanabe S, Takeuchi Y, Fukomoto S, Fujita H, Nakano T, Fujita T 2003 Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Metab 21:166-171
22. Rzonca SO, Suva LJ, Gaddy SC, Montague DC, Lecka-Czernik B 2004 Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401-406
23. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H 2004 PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113:846-855
24. Ali AA, Weinstein RA, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL 2005 Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146:1226-1235
25. Keegan TH, Schwartz AV, Bauer DC, Sellmeyer DE, Kelsey JL 2004 Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the Fracture Intervention Trial. Diabetes Care 27:1547-1553